Knight-Swift Transportation Holdings Inc. vs ResMed Inc. — how do they compare? Knight-Swift Transportation Holdings Inc. trades at $64.4 (market cap $10.59B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 3× Knight-Swift Transportation Holdings Inc.'s market cap, and Knight-Swift Transportation Holdings Inc. pays the higher dividend (1.23%). Which is the better fit depends on your goals — on Pluang, investors hold Knight-Swift Transportation Holdings Inc. for 1 Days and ResMed Inc. for 51 Days on average.
| KNX | RMD | |
|---|---|---|
Market Cap | $10.59B | $31.89B |
Volume | 2,972,511 | 618,314 |
Sector | Industrials | Health |
52-Week High | $82.45 | $277.88 |
52-Week Low | $41.68 | $182.82 |
Typical Hold Time | 1 Days | 51 Days |
Enterprise Value | $13.09B | $31.24B |
Dividend Yield | 1.23% | 1.16% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Trailing returns across standard periods
Knight-Swift provides truckload, less-than-truckload, logistics, and freight management services. It operates a large transportation network across North America.
Read more on KNX →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →